US · BNGO
Bionano Genomics, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- San Diego, CA 92121
- Website
- bionanogenomics.com
Price · as of 2024-12-31
$1.18
Market cap 3.78M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $74.84 | +6,242.37% |
| Intrinsic Value(DCF) | $1.63 | +38.14% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $354.77 | +29,965.25% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $2,634.00 | $94,127.09 | $8,611.85 | $0.00 | $0.00 |
| 2019 | $456.00 | $37,443.51 | $1,795.77 | $0.00 | $477,137.26 |
| 2020 | $5,628.00 | $2,253.69 | $0.00 | $0.00 | $1,663.92 |
| 2021 | $1,068.00 | $437.39 | $6,236.63 | $0.00 | $0.00 |
| 2022 | $720.00 | $298.23 | $28,148.41 | $0.00 | $0.00 |
| 2023 | $68.40 | $27.36 | $238.60 | $0.00 | $0.00 |
| 2024 | $4.08 | $74.84 | $0.00 | $0.00 | $354.77 |
AI valuation
Our deep-learning model estimates Bionano Genomics, Inc.'s (BNGO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $74.84
- Current price
- $1.18
- AI upside
- +6,242.37%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.63
+38.14% upside
Graham-Dodd
—
— upside
Graham Formula
$354.77
+29,965.25% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BNGO | Bionano Genomics, Inc. | $1.18 | 3.78M | +6,242% | +38% | — | +29,965% | -0.07 | 0.22 | 0.25 | -0.26 | — | 0.30 | 1.23% | -337.87% | -363.98% | -170.33% | -128.38% | -76.97% | 0.77 | -359.80 | 1.06 | 0.38 | -0.19 | -9964.00% | -1479.00% | -4559.00% | -889.15% | -1.85 | -85.22% | 0.00% | 0.00% | 558.30% | -0.25 | -0.37 | 0.83 | -16.59 |
| BNBX | BNB Plus Corp. | $0.71 | 910.41K | — | — | — | — | -0.10 | 0.67 | 0.73 | -0.01 | — | 0.67 | 39.26% | -750.92% | -709.46% | — | — | — | 0.08 | — | 0.91 | 0.77 | 0.09 | — | — | — | -826.25% | -5.08 | — | 0.00% | 0.00% | 0.00% | 0.00 | -0.01 | 0.04 | -130.76 |
| KTTA | Pasithea Therapeutics Cor… | $0.88 | 6.56M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| MYNZ | Mainz Biomed B.V. | $0.76 | 3.11M | +29,917% | +195% | — | — | -0.25 | 0.90 | 6.08 | -0.13 | -0.02 | 1.79 | 64.31% | -2091.23% | -2421.80% | -465.82% | -559.63% | -151.15% | 0.54 | -17.39 | 1.32 | 1.08 | 0.15 | 128025.00% | -17.00% | -2724.00% | -319.32% | -2.87 | -519.21% | 0.00% | 0.00% | 61.01% | -0.13 | -0.14 | 2.76 | -13.59 |
| NDRA | ENDRA Life Sciences Inc. | $4.15 | 3.12M | — | — | — | — | -0.34 | 1.54 | — | -0.12 | -0.46 | 1.54 | 0.00% | — | — | -280.02% | -690.14% | -205.38% | 0.23 | — | 5.67 | 5.34 | 0.25 | 7402.00% | — | -2260.00% | -188.25% | -12.23 | -473.18% | 0.13% | 0.00% | 5.35% | -0.12 | -0.17 | — | -38.53 |
| POAI | Predictive Oncology Inc. | $1.87 | 1.36M | +2,229% | +265% | — | -66% | -8.59 | -460.28 | 57.43 | -9.24 | — | -225.96 | 49.12% | -673.69% | -751.39% | -269.18% | -631.77% | -112.02% | -10.52 | — | 0.62 | 0.41 | -0.14 | -3563.00% | -878.00% | -1859.00% | -11.78% | -3.05 | -634.35% | 0.00% | 0.00% | 0.00% | -8.65 | -8.62 | 58.29 | -47.25 |
| QNRX | Quoin Pharmaceuticals, Lt… | $8.37 | 4.92M | — | — | — | — | -0.16 | 0.16 | — | 1.34 | — | 0.17 | 0.00% | — | — | -121.13% | 192.82% | -64.60% | 0.00 | — | 3.57 | 3.36 | 0.38 | -8019.00% | — | -9.00% | -540.58% | -1.88 | 159.01% | 0.00% | 0.00% | 84.08% | 1.32 | 1.60 | — | -5.96 |
| VYNE | VYNE Therapeutics Inc. | $0.60 | 10.01M | +3,912% | -43% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
| XTLB | XTL Biopharmaceuticals Lt… | $0.76 | 1.04M | — | +76% | — | — | -2.05 | 0.39 | 4.66 | -1.18 | — | -1.34 | 0.67% | -481.60% | -227.72% | -26.83% | -83.03% | -18.71% | 0.03 | -25.26 | 0.61 | 0.56 | 0.25 | — | — | 13649.00% | -79.50% | -0.73 | -72.01% | 0.00% | 0.00% | 0.00% | -0.51 | -0.66 | 2.44 | -26.54 |
About Bionano Genomics, Inc.
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
- CEO
- Robert Erik Holmlin
- Employees
- 98
- Beta
- 1.69
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.63 ÷ $1.18) − 1 = +38.14% (DCF, example).